These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15819867)

  • 1. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
    Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
    Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
    J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
    Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66).
    Wu JJ; Chen HM; Ko WC; Wu HM; Tsai SH; Yan JJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):169-75. PubMed ID: 17913434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
    Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
    Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
    Cremet L; Bemer P; Rome J; Juvin ME; Navas D; Bourigault C; Guillouzouic A; Caroff N; Lepelletier D; Asseray N; Perrouin-Verbe B; Corvec S
    Scand J Infect Dis; 2011 Dec; 43(11-12):957-61. PubMed ID: 21888562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
    Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
    Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
    Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase.
    Tsakris A; Ikonomidis A; Poulou A; Spanakis N; Pournaras S; Markou F
    J Antimicrob Chemother; 2007 Jul; 60(1):136-9. PubMed ID: 17491004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
    Kwiecińska-Piróg J; Bogiel T; Gospodarek E
    Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002.
    Ho PL; Ho AY; Chow KH; Wong RC; Duan RS; Ho WL; Mak GC; Tsang KW; Yam WC; Yuen KY
    J Antimicrob Chemother; 2005 Jun; 55(6):840-5. PubMed ID: 15857942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis.
    Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K
    J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101
    [No Abstract]   [Full Text] [Related]  

  • 16. Regional Spread of CTX-M-2-Producing Proteus mirabilis with the Identical Genetic Structure in Japan.
    Kato K; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
    Microb Drug Resist; 2017 Jul; 23(5):590-595. PubMed ID: 27834610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Salmonella genomic island 1 (SGI1) among Proteus mirabilis clinical isolates in Dijon, France.
    Siebor E; Neuwirth C
    J Antimicrob Chemother; 2013 Aug; 68(8):1750-6. PubMed ID: 23580563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of plasmid-encoded extended spectrum beta-lactamases produced by a clinical strain of Proteus mirabilis.
    Mahrouki S; Ben-Achour N; Chouchani C; Ben-Moussa M; Belhadj O
    Pathol Biol (Paris); 2009 May; 57(3):e55-9. PubMed ID: 18456422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
    Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
    J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.